Elliott Kieff
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Elliott Kieff has a total of 200 co-authors. Here are the top co-authors by number of shared publications:
Bo Zhao
Department of Medicine and Microbiology and Immunobiology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115
19 shared publicationsEric Johannsen
Departments of Medicine and Microbiology and Molecular Genetics, and
16 shared publicationsEllen Cahir-McFarland
The Department of Medicine, Division of Infectious Disease, Brigham and Women's Hospital and the Department of Microbiology and Molecular Genetics, Harvard Medical School, Boston, Massachusetts, United States of America
13 shared publicationsBenjamin E. Gewurz
Division of Infectious Disease, Department of Medicine, Microbiology and Immunobiology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115
7 shared publicationsSeiji Maruo
Department of Tumor Virology, Institute for Genetic Medicine, Hokkaido University, Sapporo 060-0815, Japan; and
7 shared publicationsVishal Soni
Channing Laboratory and Infectious Diseases Division, Brigham and Women's Hospital, Department of Medicine and Department of Microbiology and Molecular Genetics, Harvard Medical School, Boston, Massachusetts 02115
7 shared publications
Latest Publications
- 18 November 2016
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 113 (49) , 14121-14126
Epstein–Barr virus super-enhancer eRNAs are essential for MYC oncogene expression and lymphoblast proliferation
Significance: EBV infection causes African Burkitt's lymphoma; Hodgkin's disease; lymphomas in immune suppressed people, including HIV infected people; nasopharyngeal carcinoma; and ∼10% of gastric carcinomas. We recently found EBV super-enhancer (ESE) to be critical for lymphoblastoid cell (LCL) growth and survival. We now identified an ESE constituent, enhancer RNA (eRNA), that is important for ESE function. These eRNAs were activated by viral transactivator, EBV nuclear antigen 2 (EBNA2). MYC oncogene ESE eRNAs were able to enhance ESE activation of MYC expression and are essential for LCL growth. Targeting ESE eRNAs may lead to new therapeutics for EBV-associated malignancies.
- 18 November 2016
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 113 (49) , 14121-14126
Epstein–Barr virus super-enhancer eRNAs are essential for MYC oncogene expression and lymphoblast proliferation
Significance: EBV infection causes African Burkitt's lymphoma; Hodgkin's disease; lymphomas in immune suppressed people, including HIV infected people; nasopharyngeal carcinoma; and ∼10% of gastric carcinomas. We recently found EBV super-enhancer (ESE) to be critical for lymphoblastoid cell (LCL) growth and survival. We now identified an ESE constituent, enhancer RNA (eRNA), that is important for ESE function. These eRNAs were activated by viral transactivator, EBV nuclear antigen 2 (EBNA2). MYC oncogene ESE eRNAs were able to enhance ESE activation of MYC expression and are essential for LCL growth. Targeting ESE eRNAs may lead to new therapeutics for EBV-associated malignancies.
- 8 February 2016
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 113 (8) , 2229-2234
Ribosome Protein L4 is essential for Epstein–Barr Virus Nuclear Antigen 1 function
Significance: Epstein–Barr Virus (EBV) Nuclear Antigen 1 (EBNA1) is essential for establishing long-term EBV infection in human cells and is implicated in EBV-related malignancies. The maintenance of the EBV genome and viral gene expression from the episome are specifically driven by EBNA1 through binding to origin of plasmid replication (oriP). This study finds that EBNA1 complexes with Ribosome Protein L4 (RPL4) and Nucleolin to stabilize EBNA1 binding to oriP. Cooperation of RPL4’s N terminus with Nucleolin K429 is necessary for EBNA1 oriP binding and episome maintenance, whereas RPL4's C-terminal K380 and K393 induce H3K4me2, which promotes EBNA1 transactivation of oriP. These discoveries enhance our understanding of the complexity of EBNA1’s interactions with host proteins and EBV episomes and reveal new targets for inhibition of EBV genome persistence.
- 8 February 2016
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 113 (8) , 2229-2234
Ribosome Protein L4 is essential for Epstein–Barr Virus Nuclear Antigen 1 function
Significance: Epstein–Barr Virus (EBV) Nuclear Antigen 1 (EBNA1) is essential for establishing long-term EBV infection in human cells and is implicated in EBV-related malignancies. The maintenance of the EBV genome and viral gene expression from the episome are specifically driven by EBNA1 through binding to origin of plasmid replication (oriP). This study finds that EBNA1 complexes with Ribosome Protein L4 (RPL4) and Nucleolin to stabilize EBNA1 binding to oriP. Cooperation of RPL4’s N terminus with Nucleolin K429 is necessary for EBNA1 oriP binding and episome maintenance, whereas RPL4's C-terminal K380 and K393 induce H3K4me2, which promotes EBNA1 transactivation of oriP. These discoveries enhance our understanding of the complexity of EBNA1’s interactions with host proteins and EBV episomes and reveal new targets for inhibition of EBV genome persistence.
- 24 August 2015
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 112 (37) , 11612-11617
Evasion of affinity-based selection in germinal centers by Epstein–Barr virus LMP2A
Significance: Epstein–Barr virus (EBV) is a human herpesvirus that establishes persistent infection of the B-cell compartment. EBV is associated with autoimmune diseases, including systemic lupus erythematosus (SLE). However, the molecular mechanisms by which EBV contributes to autoimmunity remain unclear. We used previously undescribed mouse models to study the role of EBV-encoded latent membrane protein 2A (LMP2A), which mimics B-cell receptor signaling. Interestingly, LMP2A not only enhanced B-cell survival but also upregulated the transcription factor zinc finger and bric-a-brac, tramtrack domain-containing protein 20 and promoted plasma cell differentiation. When expressed late in B-cell development, LMP2A also caused prominent features of SLE, including autoantibody production with kidney immune complex deposition. Our findings suggest that LMP2A has important roles in B-cell activation and differentiation and in the development of EBV-associated autoimmune diseases.
- 24 August 2015
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 112 (37) , 11612-11617
Evasion of affinity-based selection in germinal centers by Epstein–Barr virus LMP2A
Significance: Epstein–Barr virus (EBV) is a human herpesvirus that establishes persistent infection of the B-cell compartment. EBV is associated with autoimmune diseases, including systemic lupus erythematosus (SLE). However, the molecular mechanisms by which EBV contributes to autoimmunity remain unclear. We used previously undescribed mouse models to study the role of EBV-encoded latent membrane protein 2A (LMP2A), which mimics B-cell receptor signaling. Interestingly, LMP2A not only enhanced B-cell survival but also upregulated the transcription factor zinc finger and bric-a-brac, tramtrack domain-containing protein 20 and promoted plasma cell differentiation. When expressed late in B-cell development, LMP2A also caused prominent features of SLE, including autoantibody production with kidney immune complex deposition. Our findings suggest that LMP2A has important roles in B-cell activation and differentiation and in the development of EBV-associated autoimmune diseases.
- Open Access
- 19 August 2015
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 112 (35) , 11036-11041
Nonmuscle myosin heavy chain IIA mediates Epstein–Barr virus infection of nasopharyngeal epithelial cells
Significance: EBV causes nasopharyngeal carcinoma (NPC), an endemic disease in southern China. Unlike EBV infection of B lymphocytes, the molecular mechanisms and outcomes of EBV infection of epithelial cells are poorly understood. In vitro, EBV infects B lymphoma Mo-MLV insertion region 1 homolog (BMI1)-immortalized nasopharyngeal epithelial cells (NPECs) poorly. We have now established a protocol to infect sphere-like cells derived from monolayer NPECs with EBV. Using this model system, we identified nonmuscle myosin heavy chain IIA (NMHC-IIA) as an important host factor to mediate EBV infection of NPECs. NMHC-IIA knock-down substantially decreased NPEC EBV infection. This improved EBV infection model is likely to enable new insights into the mechanisms of EBV epithelia cell infection and will be useful for the understanding EBV’s role and effects in conversion of NPECs to NPC.
- 19 August 2015
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 112 (35) , 11036-11041
Open AccessNonmuscle myosin heavy chain IIA mediates Epstein–Barr virus infection of nasopharyngeal epithelial cells
Significance: EBV causes nasopharyngeal carcinoma (NPC), an endemic disease in southern China. Unlike EBV infection of B lymphocytes, the molecular mechanisms and outcomes of EBV infection of epithelial cells are poorly understood. In vitro, EBV infects B lymphoma Mo-MLV insertion region 1 homolog (BMI1)-immortalized nasopharyngeal epithelial cells (NPECs) poorly. We have now established a protocol to infect sphere-like cells derived from monolayer NPECs with EBV. Using this model system, we identified nonmuscle myosin heavy chain IIA (NMHC-IIA) as an important host factor to mediate EBV infection of NPECs. NMHC-IIA knock-down substantially decreased NPEC EBV infection. This improved EBV infection model is likely to enable new insights into the mechanisms of EBV epithelia cell infection and will be useful for the understanding EBV’s role and effects in conversion of NPECs to NPC.
- 1 February 2015
- Published by Elsevier in Cell Host & Microbe
- Vol. 17 (2) , 205-216
Epstein-Barr Virus Oncoprotein Super-enhancers Control B Cell Growth
- 1 February 2015
- Published by Elsevier in Cell Host & Microbe
- Vol. 17 (2) , 205-216
Epstein-Barr Virus Oncoprotein Super-enhancers Control B Cell Growth
- 24 December 2014
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 112 (2) , 554-559
Epstein–Barr virus nuclear antigen 3A partially coincides with EBNA3C genome-wide and is tethered to DNA through BATF complexes
Epstein–Barr Virus (EBV) conversion of B-lymphocytes to Lymphoblastoid Cell Lines (LCLs) requires four EBV nuclear antigen (EBNA) oncoproteins: EBNA2, EBNALP, EBNA3A, and EBNA3C. EBNA2 and EBNALP associate with EBV and cell enhancers, up-regulate the EBNA promoter, MYC, and EBV Latent infection Membrane Proteins (LMPs), which up-regulate BCL2 to protect EBV-infected B-cells from MYC proliferation-induced cell death. LCL proliferation induces p16INK4A and p14ARF-mediated cell senescence. EBNA3A and EBNA3C jointly suppress p16INK4A and p14ARF, enabling continuous cell proliferation. Analyses of the EBNA3A human genome-wide ChIP-seq landscape revealed 37% of 10,000 EBNA3A sites to be at strong enhancers; 28% to be at weak enhancers; 4.4% to be at active promoters; and 6.9% to be at weak and poised promoters. EBNA3A colocalized with BATF-IRF4, ETS-IRF4, RUNX3, and other B-cell Transcription Factors (TFs). EBNA3A sites clustered into seven unique groups, with differing B-cell TFs and epigenetic marks. EBNA3A coincidence with BATF-IRF4 or RUNX3 was associated with stronger EBNA3A ChIP-Seq signals. EBNA3A was at MYC, CDKN2A/B, CCND2, CXCL9/10, and BCL2, together with RUNX3, BATF, IRF4, and SPI1. ChIP-re-ChIP revealed complexes of EBNA3A on DNA with BATF. These data strongly support a model in which EBNA3A is tethered to DNA through a BATF-containing protein complexes to enable continuous cell proliferation.
- 24 December 2014
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 112 (2) , 554-559
Epstein–Barr virus nuclear antigen 3A partially coincides with EBNA3C genome-wide and is tethered to DNA through BATF complexes
Epstein–Barr Virus (EBV) conversion of B-lymphocytes to Lymphoblastoid Cell Lines (LCLs) requires four EBV nuclear antigen (EBNA) oncoproteins: EBNA2, EBNALP, EBNA3A, and EBNA3C. EBNA2 and EBNALP associate with EBV and cell enhancers, up-regulate the EBNA promoter, MYC, and EBV Latent infection Membrane Proteins (LMPs), which up-regulate BCL2 to protect EBV-infected B-cells from MYC proliferation-induced cell death. LCL proliferation induces p16INK4A and p14ARF-mediated cell senescence. EBNA3A and EBNA3C jointly suppress p16INK4A and p14ARF, enabling continuous cell proliferation. Analyses of the EBNA3A human genome-wide ChIP-seq landscape revealed 37% of 10,000 EBNA3A sites to be at strong enhancers; 28% to be at weak enhancers; 4.4% to be at active promoters; and 6.9% to be at weak and poised promoters. EBNA3A colocalized with BATF-IRF4, ETS-IRF4, RUNX3, and other B-cell Transcription Factors (TFs). EBNA3A sites clustered into seven unique groups, with differing B-cell TFs and epigenetic marks. EBNA3A coincidence with BATF-IRF4 or RUNX3 was associated with stronger EBNA3A ChIP-Seq signals. EBNA3A was at MYC, CDKN2A/B, CCND2, CXCL9/10, and BCL2, together with RUNX3, BATF, IRF4, and SPI1. ChIP-re-ChIP revealed complexes of EBNA3A on DNA with BATF. These data strongly support a model in which EBNA3A is tethered to DNA through a BATF-containing protein complexes to enable continuous cell proliferation.
- 16 December 2013
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 111 (1) , 243-248
Nucleolin is important for Epstein–Barr virus nuclear antigen 1-mediated episome binding, maintenance, and transcription
Epstein–Barr virus (EBV) nuclear antigen 1 (EBNA1) is essential for EBV episome maintenance, replication, and transcription. These effects are mediated by EBNA1 binding to cognate oriP DNA, which comprise 20 imperfect copies of a 30-bp dyad symmetry enhancer and an origin for DNA replication. To identify cell proteins essential for these EBNA1 functions, EBNA1 associated cell proteins were immune precipitated and analyzed by liquid chromatography-tandem mass spectrometry. Nucleolin (NCL) was identified to be EBNA1 associated. EBNA19s N-terminal 100 aa and NCL9s RNA-binding domains were critical for EBNA1/NCL interaction. Lentivirus shRNA-mediated NCL depletion substantially reduced EBNA1 recruitment to oriP DNA, EBNA1-dependent transcription of an EBV oriP luciferase reporter, and EBV genome maintenance in lymphoblastoid cell lines. NCL RNA-binding domain K429 was critical for ATP and EBNA1 binding. NCL overexpression increased EBNA1 binding to oriP and transcription, whereas NCL K429A was deficient. Moreover, NCL silencing impaired lymphoblastoid cell line growth. These experiments reveal a surprisingly critical role for NCL K429 in EBNA1 episome maintenance and transcription, which may be a target for therapeutic intervention. Significance Epstein–Barr Virus (EBV) genome persistence and expression in human cells can result in human lymphocyte or epithelial cell malignancies. EBV genome persistence and gene expression depends on the EBV encoded Epstein–Barr virus nuclear antigen 1 (EBNA1) protein binding to cognate sites in EBV episomes. Search for a cell protein necessary for EBNA1 interaction with EBV episomes identified a low-level nucleolin (NCL) association with EBNA1. Despite low-level stable association, NCL shRNA knockdowns revealed wild-type NCL, but not an NCL ATP binding site point mutant to be critical for EBNA1 binding to EBV episomes, transcription, and genome maintenance. These experiments identify NCL and NCL K429 as potential targets for inhibition of EBNA1’s role in EBV oncogenesis.
- 16 December 2013
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 111 (1) , 243-248
Nucleolin is important for Epstein–Barr virus nuclear antigen 1-mediated episome binding, maintenance, and transcription
Epstein–Barr virus (EBV) nuclear antigen 1 (EBNA1) is essential for EBV episome maintenance, replication, and transcription. These effects are mediated by EBNA1 binding to cognate oriP DNA, which comprise 20 imperfect copies of a 30-bp dyad symmetry enhancer and an origin for DNA replication. To identify cell proteins essential for these EBNA1 functions, EBNA1 associated cell proteins were immune precipitated and analyzed by liquid chromatography-tandem mass spectrometry. Nucleolin (NCL) was identified to be EBNA1 associated. EBNA19s N-terminal 100 aa and NCL9s RNA-binding domains were critical for EBNA1/NCL interaction. Lentivirus shRNA-mediated NCL depletion substantially reduced EBNA1 recruitment to oriP DNA, EBNA1-dependent transcription of an EBV oriP luciferase reporter, and EBV genome maintenance in lymphoblastoid cell lines. NCL RNA-binding domain K429 was critical for ATP and EBNA1 binding. NCL overexpression increased EBNA1 binding to oriP and transcription, whereas NCL K429A was deficient. Moreover, NCL silencing impaired lymphoblastoid cell line growth. These experiments reveal a surprisingly critical role for NCL K429 in EBNA1 episome maintenance and transcription, which may be a target for therapeutic intervention. Significance Epstein–Barr Virus (EBV) genome persistence and expression in human cells can result in human lymphocyte or epithelial cell malignancies. EBV genome persistence and gene expression depends on the EBV encoded Epstein–Barr virus nuclear antigen 1 (EBNA1) protein binding to cognate sites in EBV episomes. Search for a cell protein necessary for EBNA1 interaction with EBV episomes identified a low-level nucleolin (NCL) association with EBNA1. Despite low-level stable association, NCL shRNA knockdowns revealed wild-type NCL, but not an NCL ATP binding site point mutant to be critical for EBNA1 binding to EBV episomes, transcription, and genome maintenance. These experiments identify NCL and NCL K429 as potential targets for inhibition of EBNA1’s role in EBV oncogenesis.
- 16 December 2013
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 111 (1) , 421-426
Epstein–Barr Virus Nuclear Antigen 3C binds to BATF/IRF4 or SPI1/IRF4 composite sites and recruits Sin3A to repress CDKN2A
Significance: Epstein–Barr virus (EBV) is an important causative agent of B-cell lymphomas and Hodgkin disease in immune-deficient people, including HIV-infected people. The experiments described here were undertaken to determine the mechanisms through which the EBV-encoded nuclear protein EBNA3C blocks the cell p14 ARF and p16 INK4A tumor suppressor-mediated inhibition of EBV-infected B-cell growth, thereby unfettering EBV-driven B-cell proliferation. The experiments also identify the molecular basis for diverse EBNA3C enhancer interactions with cell DNA-binding proteins and cell DNA to regulate MYC, pRB, BCL2, and BIM expression. Surprisingly, EBNA3C’s role in enhancer-mediated cell gene transcription up-regulation is primarily mediated by combinatorial effects with cell transcription factors, most notably AICEs, EICEs, and RUNX3.
- 16 December 2013
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 111 (1) , 421-426
Epstein–Barr Virus Nuclear Antigen 3C binds to BATF/IRF4 or SPI1/IRF4 composite sites and recruits Sin3A to repress CDKN2A
Significance: Epstein–Barr virus (EBV) is an important causative agent of B-cell lymphomas and Hodgkin disease in immune-deficient people, including HIV-infected people. The experiments described here were undertaken to determine the mechanisms through which the EBV-encoded nuclear protein EBNA3C blocks the cell p14 ARF and p16 INK4A tumor suppressor-mediated inhibition of EBV-infected B-cell growth, thereby unfettering EBV-driven B-cell proliferation. The experiments also identify the molecular basis for diverse EBNA3C enhancer interactions with cell DNA-binding proteins and cell DNA to regulate MYC, pRB, BCL2, and BIM expression. Surprisingly, EBNA3C’s role in enhancer-mediated cell gene transcription up-regulation is primarily mediated by combinatorial effects with cell transcription factors, most notably AICEs, EICEs, and RUNX3.
- 28 October 2013
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 110 (46) , 18537-18542
Epstein–Barr virus nuclear antigen leader protein localizes to promoters and enhancers with cell transcription factors and EBNA2
Epstein–Barr virus (EBV) nuclear antigens EBNALP (LP) and EBNA2 (E2) are coexpressed in EBV-infected B lymphocytes and are critical for lymphoblastoid cell line outgrowth. LP removes NCOR and RBPJ repressive complexes from promoters, enhancers, and matrix-associated deacetylase bodies, whereas E2 activates transcription from distal enhancers. LP ChIP-seq analyses identified 19,224 LP sites of which ∼50% were ±2 kb of a transcriptional start site. LP sites were enriched for B-cell transcription factors (TFs), YY1, SP1, PAX5, BATF, IRF4, ETS1, RAD21, PU.1, CTCF, RBPJ, ZNF143, SMC3, NFκB, TBLR, and EBF. E2 sites were also highly enriched for LP-associated cell TFs and were more highly occupied by RBPJ and EBF. LP sites were highly marked by H3K4me3, H3K27ac, H2Az, H3K9ac, RNAPII, and P300, indicative of activated transcription. LP sites were 29% colocalized with E2 (LP/E2). LP/E2 sites were more similar to LP than to E2 sites in associated cell TFs, RNAPII, P300, and histone H3K4me3, H3K9ac, H3K27ac, and H2Az occupancy, and were more highly transcribed than LP or E2 sites. Gene affected by CTCF and LP cooccupancy were more highly expressed than genes affected by CTCF alone. LP was at myc enhancers and promoters and of MYC regulated ccnd2, 23 med complex components, and MYC regulated cell survival genes, igf2r and bcl2. These data implicate LP and associated TFs and DNA looping factors CTCF, RAD21, SMC3, and YY1/INO80 chromatin-remodeling complexes in repressor depletion and gene activation necessary for lymphoblastoid cell line growth and survival. Significance Epstein–Barr virus nuclear antigen (EBNA) leader protein (LP) and EBNA2 (E2) up-regulation of virus and cell gene expression is important for human B-lymphocyte conversion to continuous, potentially malignant, lymphoblast cell lines. Although the molecular mechanism(s) underlying LP and E2 regulation of cell gene expression have been partially elucidated, LP ChIP-sequencing studies have now revealed that LP and LP/E2 interact, genome-wide, with human B-cell transcription factors, mostly at or near prepatterned promoter sites, to increase cell transcription factor occupancies, increase activation-associated histone marks, and positively affect cell gene transcription.
- 28 October 2013
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 110 (46) , 18537-18542
Epstein–Barr virus nuclear antigen leader protein localizes to promoters and enhancers with cell transcription factors and EBNA2
Epstein–Barr virus (EBV) nuclear antigens EBNALP (LP) and EBNA2 (E2) are coexpressed in EBV-infected B lymphocytes and are critical for lymphoblastoid cell line outgrowth. LP removes NCOR and RBPJ repressive complexes from promoters, enhancers, and matrix-associated deacetylase bodies, whereas E2 activates transcription from distal enhancers. LP ChIP-seq analyses identified 19,224 LP sites of which ∼50% were ±2 kb of a transcriptional start site. LP sites were enriched for B-cell transcription factors (TFs), YY1, SP1, PAX5, BATF, IRF4, ETS1, RAD21, PU.1, CTCF, RBPJ, ZNF143, SMC3, NFκB, TBLR, and EBF. E2 sites were also highly enriched for LP-associated cell TFs and were more highly occupied by RBPJ and EBF. LP sites were highly marked by H3K4me3, H3K27ac, H2Az, H3K9ac, RNAPII, and P300, indicative of activated transcription. LP sites were 29% colocalized with E2 (LP/E2). LP/E2 sites were more similar to LP than to E2 sites in associated cell TFs, RNAPII, P300, and histone H3K4me3, H3K9ac, H3K27ac, and H2Az occupancy, and were more highly transcribed than LP or E2 sites. Gene affected by CTCF and LP cooccupancy were more highly expressed than genes affected by CTCF alone. LP was at myc enhancers and promoters and of MYC regulated ccnd2, 23 med complex components, and MYC regulated cell survival genes, igf2r and bcl2. These data implicate LP and associated TFs and DNA looping factors CTCF, RAD21, SMC3, and YY1/INO80 chromatin-remodeling complexes in repressor depletion and gene activation necessary for lymphoblastoid cell line growth and survival. Significance Epstein–Barr virus nuclear antigen (EBNA) leader protein (LP) and EBNA2 (E2) up-regulation of virus and cell gene expression is important for human B-lymphocyte conversion to continuous, potentially malignant, lymphoblast cell lines. Although the molecular mechanism(s) underlying LP and E2 regulation of cell gene expression have been partially elucidated, LP ChIP-sequencing studies have now revealed that LP and LP/E2 interact, genome-wide, with human B-cell transcription factors, mostly at or near prepatterned promoter sites, to increase cell transcription factor occupancies, increase activation-associated histone marks, and positively affect cell gene transcription.
- 1 January 2013
- Published by Bio-Protocol, LLC in Bio-Protocol
- Vol. 3 (18)
Chromatin Immunoprecipitation (ChIP), Streptavidin and ATP-agarose Mediated Pull-down Analyses
Epstein-Barr virus (EBV) nuclear antigen 2 (EBNA2) induces expression of both viral and cellular genes in virus infected B cells by mimicking activated Notch receptors (Notch-IC) that mediate transcription activation through binding to the repressing domain of the recombining binding protein suppressor of hairless (RBP-Jκ). In general, chromatin immunoprecipitation (ChIP) assays, electrophoresis mobility shift assays (EMSA), streptavidin-agarose mediated DNA pull-down assays, together with cell-based transcription reporter assays were conducted to verify whether the query protein is involved in EBNA2-dependent transcription. The ATP-bound state of nuclear chaperone nucleophosmin (NPM1) has been implicated in pleiotropic biological processes. An ATP-agarose-mediated pull-down protocol was developed to monitor the formation of the pre-initiation complex that is induced by ATP-bound NPM1. According to EBNA2 and Notch-IC have been shown to be partially interchangeable with respect to activation of target genes in B cell lines, it is conceivable that EBNA2 is a biological equivalent of an activated Notch IC.
- 1 January 2013
- Published by Bio-Protocol, LLC in Bio-Protocol
- Vol. 3 (18)
Chromatin Immunoprecipitation (ChIP), Streptavidin and ATP-agarose Mediated Pull-down Analyses
Epstein-Barr virus (EBV) nuclear antigen 2 (EBNA2) induces expression of both viral and cellular genes in virus infected B cells by mimicking activated Notch receptors (Notch-IC) that mediate transcription activation through binding to the repressing domain of the recombining binding protein suppressor of hairless (RBP-Jκ). In general, chromatin immunoprecipitation (ChIP) assays, electrophoresis mobility shift assays (EMSA), streptavidin-agarose mediated DNA pull-down assays, together with cell-based transcription reporter assays were conducted to verify whether the query protein is involved in EBNA2-dependent transcription. The ATP-bound state of nuclear chaperone nucleophosmin (NPM1) has been implicated in pleiotropic biological processes. An ATP-agarose-mediated pull-down protocol was developed to monitor the formation of the pre-initiation complex that is induced by ATP-bound NPM1. According to EBNA2 and Notch-IC have been shown to be partially interchangeable with respect to activation of target genes in B cell lines, it is conceivable that EBNA2 is a biological equivalent of an activated Notch IC.